Endocyte announces presentations at AACR Annual Meeting 2013

Published: April 3, 2013

WEST LAFAYETTE, Ind. - Endocyte Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that four poster presentations will be presented by Endocyte scientists at the 2013 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington, D.C., April 6-10, 2013.

"Significant advances were made to our SDMC technology platform over the past year which collectively have led to the discovery of several new lead molecules that are currently in preclinical development," said Christopher Leamon, Ph.D., vice president of research and development. "We are excited to take part in this year's AACR meeting where we will discuss the applications of our pipeline compounds for cancer therapy."

Presentations are as follows:

Abstract #:2145
Title:"PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169"
When: Monday, April 8, 1 p.m. – 5 p.m. EDT 
Session ID:  Novel Targeted Therapies 1
Location:   Hall A-C, Poster Section 40
Abstract #:4499
Title:"Total synthesis of tubulysins: A new chemical reaction leads to analogues with enhanced cytotoxicity" 
When: Tuesday, April 9, 1 p.m. – 5 p.m. EDT
Session ID: Genome and Microtubule Integrity
Location: Hall A-C, Poster Section 42
Abstract #:5623
Title:"Extracellular thiols and system xc play a significant role in non-targeted in vitro activity of a folate-tubulysin B conjugate"
When: Wednesday, April 10, 8 a.m. – noon EDT
Session ID:  Novel Delivery Technologies
Location:  Hall A-C, Poster Section 41
Abstract #:5502
Title:"Vintafolide: a first-in-class small molecule drug conjugate targeting folate receptor positive tumors"
When: Wednesday, April 10, 8 a.m. – noon EDT
Session ID:  Chemotherapy and Cancer Dependencies
Location:  Hall A-C, Poster Section 37


About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

For additional information, please visit Endocyte's website at www.endocyte.com .


CONTACT: Stephanie Ascher
         Stern Investor Relations, Inc.
         (212) 362-1200
         Martina Schwarzkopf, Ph.D.
         Russo Partners
         (212) 845-4292
         Tony Russo, Ph.D.
         Russo Partners
         (212) 845-4251